Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Cassava Sciences Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| BIL | FLNA | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $4.64 |
52-Week Low | $91.27 | $0.87 |
Market Cap | — | $47.75M |
Enterprise Value | — | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.
As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
